FDA Approves Expanded Access Program For Lipella Pharma's LP-310 In Oral Lichen Planus; Stock Up
Lipella Pharmaceuticals Inc. (LIPO), a clinical-stage biotechnology company, Wednesday said that the U.S. Food and Drug ...
FDA approves Lipella's oral treatment access program
PITTSBURGH - Lipella Pharmaceuticals Inc. (NASDAQ:LIPO), a biotech firm specializing in novel therapies for medical conditions lacking adequate treatments, has received FDA approval for an Expanded ...
Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus
The FDA’s approval for expanded use reinforces LP-310’s potential as a new therapeutic option for OLP and supports ongoing clinical development efforts.